Breast Cancer Program

项目概要-乳腺癌项目 Abramson癌症中心（ACC）的乳腺癌项目（BCP）是一个多学科团队， 富有成效的研究人员集中在一个共同的目标上：通过以下措施降低乳腺癌的负担和死亡率： 阐明疾病背后的生物学机制，并将这些知识转化为改进的 检测、预防和治疗。BCP成员高度协作，致力于互联 科学目标涵盖从基础科学到临床研究的连续体。具体目标是：1）阐明 乳腺癌发生发展的生物学、遗传学和分子机制; 2）乳腺癌的研究进展 了解遗传易感性，以优化风险人群的筛查和预防; 3）开发 创新的成像方法，以改善乳腺癌筛查，检测和生物标志物，以指导 治疗和评估治疗反应，以及4）将实验室发现转化为新的临床试验 治疗，包括反应和结果的生物标志物。成员们做出了重大发现， 确定乳腺癌驱动因素、肿瘤休眠机制和基因组完整性、干扰素反应，以及 辐射与免疫原性的关系。这些发现被转化为新的目标， 治疗，新的组合，基因组和预测分析，以及尖端的成像方法， probes.项目成员设计和实施创新的临床试验，领导临床/翻译团队 在国家和国际上，在ACC内部。在本融资期内，有1，386项应计项目 干预性试验和14，079项非干预性试验。方案的补充技能 共同负责人（PL）Angela DeMichele，MD，MSCE（临床试验/生物标志物）和Roger Greenberg，MD，PhD （基础科学/遗传学）促进计划内和计划间的合作。临床翻译基本 科学作为一个主要的重点，PLs扩大了乳腺癌和遗传学的临床研究单位，增长， 策划了大型生物标本库，并招募了优秀的高级和初级教师。这些发展 在行政协调会试验基金的支助下，促进了新的想法和合作。劳工处亦推出两项新措施， 基础科学中心，基因组完整性中心和马克基金会中心。25名成员 BCP来自七个大学部门和两个学校，反映了不同的专业知识。BCP成员 持有1040万美元的癌症相关赠款资金（年度直接成本），其中660万美元用于同行评审，430万美元用于 是国家癌症研究所资助的成员持有26个R 01或同等产品（其中六个是多PI奖项），一个NCI R33 Moonshot 格兰特和一个国防部乳腺癌卓越中心。在当前的供资周期内，BCP成员 发表了403篇与癌症相关的论文，其中22%是项目内合作，37%是项目间合作， 方案合作，72%是多机构性质的。由高级临床领导支持 在国家乳腺中心认证计划--经认证的罗文乳腺中心内，BCP生成 高影响力，改变实践的研究，在乳腺癌治疗和结果上移动针。

PROJECT SUMMARY – Breast Cancer Program The Breast Cancer Program (BCP) of the Abramson Cancer Center (ACC) is a multidisciplinary team of highly productive investigators focused on a common goal: to reduce the burden and mortality of breast cancer by elucidating biological mechanisms underlying the disease and translating this knowledge to improved detection, prevention and treatment. BCP members are highly collaborative, working on interconnected scientific aims that span the continuum from basic science to clinical research. Specific Aims are: 1) Elucidate the biologic, genetic and molecular mechanisms of breast cancer development and progression; 2) Advance understanding of genetic susceptibility to optimize screening and prevention for those at risk; 3) Develop innovative imaging approaches to improve breast cancer screening, detection and biomarkers to guide treatment and assess therapeutic response, and 4) Translate laboratory discoveries to clinical trials of novel therapeutics, incorporating biomarkers of response and outcome. Members made fundamental discoveries to identify breast cancer drivers, mechanisms of tumor dormancy and genome integrity, interferon response, and the relationship between radiation and immunogenicity. These findings were translated into new targeted therapeutics, novel combinations, genomic and predictive assays, and cutting-edge imaging methods and probes. Program members design and implement innovative clinical trials, leading clinical/translational teams within the ACC, nationally and internationally. In the current funding period, there were 1,386 accruals onto interventional trials and 14,079 accruals onto non-interventional trials. The complementary skills of Program co-Leaders (PLs) Angela DeMichele, MD, MSCE (clinical trials/biomarkers) and Roger Greenberg, MD, PhD (basic science/genetics) facilitate intra- and inter- Programmatic collaborations. With clinical translation of basic science as a major focus, the PLs expanded clinical research units for breast cancer and genetics, grew and curated large biospecimen banks, and recruited exceptional senior and junior faculty. These developments have fostered new ideas and collaborations supported by ACC pilot funds. The PLs also initiated two new basic science centers, the Center for Genome Integrity and the Mark Foundation Center. The 25 members of BCP come from seven University Departments and two Schools, reflecting diverse expertise. BCP members hold $10.4M in cancer-related grant funding (annual direct costs), of which $6.6M is peer-reviewed and $4.3M is NCI-funded. Members hold 26 R01s or equivalent (of which six are multi-PI awards), an NCI R33 Moonshot Grant, and a DOD Breast Cancer Center of Excellence. Over the current funding cycle, BCP members published 403 cancer-related papers, of which 22% were intra-Programmatic collaborations, 37% were inter- Programmatic collaborations, and 72% were multi-institutional in nature. Supported by senior clinical leaders within the National Accreditation Program for Breast Centers-accredited Rowan Breast Center, BCP generates high-impact, practice-changing research, moving the needle on breast cancer treatment and outcomes.